

Financial news for MSTX dated on 2017-04-20: Mast Therapeutics Reports Possible Adjournment of Special Shareholder Meeting for Solicitation of Added Votes for Savara Deal

Financial news for MSTX dated on 2017-04-17: Mast Releases PR Asking For Stockholders To Vote For The Proposed Merger With Savara

Financial news for MSTX dated on 2017-04-17: Mast Therapeutics Offers Reminder Holders Vote for Proposed Deal with Savara

Financial news for MSTX dated on 2017-04-11: Mast Therapeutics Reports ISS, Glass Lewis Recommend Co. Holders Vote 'FOR' Proposed Merger, Related Proposals

Financial news for MSTX dated on 2017-03-06: Mast Therapeutics Reports Q4 EPS \$(0.02) vs \$(0.04) Est., Sales \$83K

Financial news for MSTX dated on 2017-03-06: Mast Therapeutics Reports Clinical Study Agreement With University Of Pittsburgh For AIR001 For Treatment Of P. aeruginosa Infection In Cystic Fibrosis

Financial news for MSTX dated on 2017-01-09: The Market In 5 Minutes: Earnings Results, Conferences, Trump And More

Financial news for MSTX dated on 2017-01-09: Wall Street's M&A Chatter From January 6-8

Financial news for MSTX dated on 2017-01-07: Mast Therapeutics, Savara Sign Merger Agreement; Deal Values Mast @\$36.5M

Financial news for MSTX dated on 2016-12-06: Mast Therapeutics Announces Initiation Of Patient Enrollment In Additional Phase 2 Study Of AIR001 For The Treatment Of Heart Failure With Preserved Ejection Fraction

Financial news for MSTX dated on 2016-11-08: Mast Therapeutics Reports Q3 EPS \$(0.04) vs. Est. \$(0.05), Rev. \$45K

Financial news for MSTX dated on 2016-10-17: Mast Therapeutics Reports Agreement With Philips For Supply Of Adaptive Aerosol Delivery System For AIR001

Financial news for MSTX dated on 2016-09-27: 15 Biggest Mid-Day Losers For Tuesday

Financial news for MSTX dated on 2016-09-27: Mast Therapeutics Provides Clinical Developments Update; Range-Bound Trading A Mid-Term Plausibility

Financial news for MSTX dated on 2016-09-27: The Market In 5 Minutes: Debates, Oil Keep Stocks Mixed

Financial news for MSTX dated on 2016-09-27: Benzinga's Top Downgrades

Financial news for MSTX dated on 2016-09-27: Cowen & Co. Downgrades Mast Therapeutics to Market Perform

Financial news for MSTX dated on 2016-09-26: Mast Therapeutics Issues Business Update: Says Will Continue to Support Three Ongoing Investigator Sponsored Phase 2 Studies of AIR001, Has Begun to Wind Down Vepoloxamer Programs

Financial news for MSTX dated on 2016-09-21: Mid-Afternoon Market Update: Dow Surges 125 Points; FedEx Shares Jump Following Upbeat Earnings

Financial news for MSTX dated on 2016-09-21: 12 Biggest Mid-Day Losers For Wednesday

Financial news for MSTX dated on 2016-09-21: Mid-Day Market Update: Crude Oil Up 2.75%; Mast Therapeutics Shares Drop After Sickle Cell Drug Phase 3 Trial Fail

Financial news for MSTX dated on 2016-09-21: Mid-Morning Market Update: Markets Open Higher; General Mills Earnings Top Views

Financial news for MSTX dated on 2016-09-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for MSTX dated on 2016-09-20: After-Hours Decliners Sept. 20, 2016: MSTX Down 84%, MIRN 29%, BMRN 1%

Financial news for MSTX dated on 2016-09-20: Shkreli Warned You: Mast Therapeutics Plummets 80% After Sickle Cell Drug Phase 3 Trial Fail

Financial news for MSTX dated on 2016-09-20: Mast Therapeutics Shares Down 80% in After-Hours Action

Financial news for MSTX dated on 2016-09-20: UPDATE: Mast Expects To Terminate All Clinical Development Of vepoloxamer, Intends To Reduce Operating Expenses Immediately

Financial news for MSTX dated on 2016-09-20: Mast Therapeutics Reports Top-Line Results From Phase 3 Study In Sickle Cell Disease, Did Not Meet Primary Endpoint

Financial news for MSTX dated on 2016-09-19: Watch These 7 Huge Call Purchases In Monday Trade

Financial news for MSTX dated on 2016-09-16: Option Alert: MSTX Apr17 2.5 Calls Sweep: 720 @ ASK \$0.10: 772 traded vs 45k OI: \$0.56 Ref

Financial news for MSTX dated on 2016-09-13: Shkreli Thinks The Mylan-Epipen Controversy Is 'Not Very Fair'

Financial news for MSTX dated on 2016-09-12: Martin Shkreli Thinks Jazz Pharmaceuticals Could Be Worth \$20 Billion, While Mast Therapeutics Is 'Worthless'

Financial news for MSTX dated on 2016-09-12: UPDATE: Martin Shkreli on Short Opportunity in Mast Therapeutics: 'If You Can Find A Broker Who Will Let You Short The Stock, This Co. is Probably Worthless'

Financial news for MSTX dated on 2016-09-12: Martin Shkreli on Investor Opportunity in Pharma: Besides Jazz on the Long Side, 'The Only Other One I Spent Time Looking at is a Penny Stock, Mast Therapeutics,' Sees as a Short

Financial news for MSTX dated on 2016-09-12: Mast Therapeutics Releases Investor Presentation

Financial news for MSTX dated on 2016-09-01: Watch These 7 Huge Call Purchases In Thursday Trade

Financial news for MSTX dated on 2016-08-31: Option Alert: MSTX Oct16 2.5 Calls Sweep: 500 @ ASK \$0.05: 1572 traded vs 29k OI: \$0.43 Ref

Financial news for MSTX dated on 2016-08-18: 11 Biopharma CEOs To Follow On Twitter

Financial news for MSTX dated on 2016-08-09: Mast Therapeutics Reports Q2 EPS \$(0.05) vs. Est. \$(0.06)

Financial news for MSTX dated on 2016-08-01: Mast Therapeutics Reports Start Of Phase 2 Study Of AIR001 Conducted By The Heart Failure Clinical Research Network

Financial news for MSTX dated on 2016-07-26: 15 Biggest Mid-Day Losers For Tuesday

Financial news for MSTX dated on 2016-07-26: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for MSTX dated on 2016-07-14: Option Alert: MSTX Aug16 2.5 Calls Sweep: 845 @ ASK \$0.05: 845 traded vs 1606 OI: Earnings 8/10 \$0.44 Ref

Financial news for MSTX dated on 2016-06-30: Mast Therapeutics Sells Off to Low of \$0.36 on Vol

Financial news for MSTX dated on 2016-06-22: Option Alert: MSTX Jan17 2.5 Calls: 749 @ ASK \$0.10: 1055 traded vs 3045 OI: Earnings 8/10 \$0.45 Ref

Financial news for MSTX dated on 2016-06-08: Mast Therapeutics Receives Notice Of Allowance Of Composition Of Matter Patent Application Covering Vepoloxamer

Financial news for MSTX dated on 2016-05-06: Mast Therapeutics Reports Q1 EPS \$(0.06) vs. Est. \$(0.06)

Financial news for MSTX dated on 2016-04-13: Mast Therapeutics Reports Deal for Phase 2 Study of AIR001

Financial news for MSTX dated on 2016-04-13: Mast Therapeutics Announces Agreement For Phase 2 Study Of AIR001 To Be Conducted By The Heart Failure Clinical Research Network

Financial news for MSTX dated on 2016-03-14: Mast Therapeutics Reports Q4 EPS \$(0.06), Inline

Financial news for MSTX dated on 2016-02-10: Mast Therapeutics Prices 29M Unit Offering At \$0.275/Unit

Financial news for MSTX dated on 2016-02-09: Mast Therapeutics Reports Proposed Public Offering Of Stocks, Warrants

Financial news for MSTX dated on 2016-02-01: Mast Therapeutics' AIR001 Selected By The Heart Failure Clinical Research Network For Evaluation In A 100-Patient Multicenter Phase 2 Study

Financial news for MSTX dated on 2016-02-01: 10 Stocks Moving In Monday's Pre-Market Session

Financial news for MSTX dated on 2016-02-01: Mast Therapeutics Reports Top-Line Phase 2a Results, AIR001 Showed Statistically Significant Improvement From Primary Endpoint With No Adverse Events

Financial news for MSTX dated on 2016-01-07: UPDATE: Mast Says Ended '15 with ~\$41M in Cash, Cash Equivalents

Financial news for MSTX dated on 2016-01-07: UPDATE: Mast Therapeutics Says Enrollment in Phase 2a Study of AIR001 in HFpEF Closed, Top-Line Data Expected This Month

Financial news for MSTX dated on 2016-01-07: Mast Therapeutics Issues Business Update: Says Enrollment in Phase 3 Trial of Sickle Cell Disease Surpassed 90%; Top-Line Data Expected in Q2'16

Financial news for MSTX dated on 2015-12-30: Amended 13D Filing from Carl Icahn on Mast Therapeutics Shows Liquidated Position

Financial news for MSTX dated on 2015-11-12: Mast Therapeutics Reports Q3 EPS (\$0.06) vs. Est. (\$0.06)

Financial news for MSTX dated on 2015-11-12: Maxim Group Initiates Coverage on Mast Therapeutics at Buy, Announces \$5.00 PT

Financial news for MSTX dated on 2015-10-26: Mast Therapeutics Starts Phase 2 Study Of Vepoloxamer For The Treatment Of Chronic Heart Failure

Financial news for MSTX dated on 2015-09-30: Mast Reports Amendment To Loan, Security Agreement With Hercules Technology Growth Capital

Financial news for MSTX dated on 2015-05-11: Mast Therapeutics Reports Q1 Loss of \$0.06/Share, Inline

Financial news for MSTX dated on 2015-04-24: Roth Capital Initiates Coverage on Mast Therapeutics at Buy, Announces \$3.00 PT

Financial news for MSTX dated on 2015-04-21: Enrollment In Mast Therapeutics' Phase 3 "EPIC" Study In Sickle Cell Disease Passes Halfway Mark

Financial news for MSTX dated on 2015-03-24: S-3 from Mast Therapeutics Shows Registration for \$150M Mixed Securities Shelf Offering

Financial news for MSTX dated on 2015-03-24: Mast Therapeutics Reports Q4 Loss of \$0.05/Share vs Loss of \$0.06/Share Est.

Financial news for MSTX dated on 2015-03-23: Mast Therapeutics Announces Will Develop MST-188 for Chronic Heart Failure, Cites Positive Non-Clinical Study Results

Financial news for MSTX dated on 2015-03-02: Mast Announces Vepoloxamer Nonclinical Study Results In Advanced Heart Failure

Financial news for MSTX dated on 2015-02-11: Mast Therapeutics Announces New Data Supporting Vepoloxamer

Financial news for MSTX dated on 2015-01-24: Mast Therapeutics President, COO Patrick Keran to Step Down Effective February 28

Financial news for MSTX dated on 2015-01-06: Tuesday's Morning Market Movers: Minerva, El Pollo LoCo And More

Financial news for MSTX dated on 2015-01-05: Mast Therapeutics Reports Update on Epic Study Enrollment, Offers '15 Milestones

Financial news for MSTX dated on 2014-11-19: Mast Therapeutics Announces New Data From Nonclinical Heart Failure Study To Be Presented At AHA Conference

Financial news for MSTX dated on 2014-11-17: Benzinga's Top Initiations

Financial news for MSTX dated on 2014-11-17: Canaccord Genuity Initiates Mast Therapeutics With Buy

Financial news for MSTX dated on 2014-11-17: Canaccord Genuity Initiates Coverage on

Mast Therapeutics at Buy, Announces \$3.00 PT

Financial news for MSTX dated on 2014-11-05: Mast Therapeutics Announces Underwritten Public Offering

Financial news for MSTX dated on 2014-10-31: Mast Therapeutics Reports Q3 EPS of \$(0.06), Inline

Financial news for MSTX dated on 2014-10-02: Mast Therapeutics Names Edwin Parsley as Chief Medical Officer

Financial news for MSTX dated on 2014-09-08: Morning Market Movers: The Bank of Kentucky Financial Corp., BB&T Corporation & More

Financial news for MSTX dated on 2014-09-08: Benzinga's Top #PreMarket Gainers

Financial news for MSTX dated on 2014-09-08: Mast Therapeutics Reports Top-Line Results from Phase 2 Study for AIR001

Financial news for MSTX dated on 2014-08-11: Mast Therapeutics Reports Q2 EPS of \$(0.06), Inline

Financial news for MSTX dated on 2014-06-16: Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

Financial news for MSTX dated on 2014-04-14: Morning Market Movers

Financial news for MSTX dated on 2014-04-14: Mast Therapeutics Announces Positive Data Supporting MST-188 In Sickle Cell Disease

Financial news for MSTX dated on 2014-03-26: Morning Market Movers

Financial news for MSTX dated on 2014-03-26: UPDATE: Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia

Financial news for MSTX dated on 2014-03-26: Mast Therapeutics Initiates Phase 2 Study Of MST-188 In Patients With Acute Limb Ischemia

Financial news for MSTX dated on 2014-03-20: BiotechBreakthroughs Tweet: Bought \$MSTX in size. Believe this is the next small biotech to make a large move.

Financial news for MSTX dated on 2014-02-18: Mast Therapeutics Announces Additional Results from Nonclinical Heart Failure Study

Financial news for MSTX dated on 2014-01-21: Mast Therapeutics Shares Rise 10% Pre-Market; May be Attributed to Seeking Alpha Post

Financial news for MSTX dated on 2014-01-17: Mast Therapeutics Spikes Higher; May Be Related to Positive Twitter Chatter

Financial news for MSTX dated on 2014-01-13: Mast Therapeutics Shares Rise 34% Ahead of Tuesday Presentation at OneMedForum

Financial news for MSTX dated on 2014-01-08: Mast Therapeutics Provides Enrollment Update On Phase 3 "EPIC" Study Of MST-188

Financial news for MSTX dated on 2014-01-06: Mast Therapeutics Announces Positive Data In Model Of Heart Failure

Financial news for MSTX dated on 2013-11-04: Mast Therapeutics Reports Q3 EPS of \$(0.05) vs \$(0.07) Est

Financial news for MSTX dated on 2013-10-06: Bret Jensen Likes Mast Therapeutics, Curis as Speculative Biotech Plays

Financial news for MSTX dated on 2013-10-03: UPDATE: Canaccord Genuity Initiates Coverage on Mast Therapeutics on MST-188 Potential

Financial news for MSTX dated on 2013-10-03: Benzinga's Top Initiations

Financial news for MSTX dated on 2013-10-03: Canaccord Genuity Initiates Coverage on Mast Therapeutics at Buy, Announces \$3.00 PT

Financial news for MSTX dated on 2013-06-05: Mast Therapeutics Raises Size of IPO from Initial \$30M in Shares to \$34.5M